In the preceding three months, 7 analysts have released ratings for Align Tech ALGN, presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 4 | 1 | 0 | 0 |
Last 30D | 0 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 3 | 1 | 0 | 0 |
3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $361.43, with a high estimate of $400.00 and a low estimate of $320.00. Marking an increase of 8.26%, the current average surpasses the previous average price target of $333.86.
Exploring Analyst Ratings: An In-Depth Overview
The perception of Align Tech by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Erin Wright | Morgan Stanley | Raises | Overweight | $360.00 | $344.00 |
Jason Bednar | Piper Sandler | Raises | Overweight | $375.00 | $355.00 |
Jeff Johnson | Baird | Raises | Outperform | $370.00 | $333.00 |
Jonathan Block | Stifel | Raises | Buy | $400.00 | $350.00 |
Kevin Caliendo | UBS | Raises | Neutral | $320.00 | $280.00 |
Jonathan Block | Stifel | Raises | Buy | $350.00 | $340.00 |
Jason Bednar | Piper Sandler | Raises | Overweight | $355.00 | $335.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Align Tech. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Align Tech compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Align Tech's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Align Tech's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Align Tech analyst ratings.
Unveiling the Story Behind Align Tech
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
A Deep Dive into Align Tech's Financials
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Align Tech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.76% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Align Tech's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.53% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Align Tech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Align Tech's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.72%, the company showcases efficient use of assets and strong financial health.
Debt Management: Align Tech's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.